Results 31 to 40 of about 5,445 (182)

Can tolvaptan usage cause cytotoxicity? An in vitro study

, 2023
Objectives: Tolvaptan is a nonpeptide V2 (vasopressin) receptor antagonist which is commonly used for treatment of hypernatremia. Besides it is mostly used for rescue strategies of mutant V2 receptors which are responsible for congenital type of ...
TUNÇDEMİR, Beril ERDEM, Beril ERDEM TUNÇDEMİR   +1 more
core   +1 more source

Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients.

, 2022
BACKGROUND Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of Tolvaptan treatment on mineral metabolism and bone mineral density is unknown.
Nasser A Dhayat, Bargagli, Matteo, Daniel G Fuster, Anderegg, Manuel A, Faller, Nicolas, Fuster, Daniel G, Matteo Bargagli, Manuel A Anderegg, Vogt, Bruno, Uyen Huynh-Do, Ferraro, Pietro Manuel, Huynh-Do, Uyen, Nicolas Faller, Pietro Manuel Ferraro, Dhayat, Nasser A, Bruno Vogt, Andri Vetsch, Vetsch, Andri   +17 more
core   +1 more source

Tolvaptan Attenuates Left Ventricular Fibrosis After Acute Myocardial Infarction in Rats

Journal of Pharmacological Sciences, 2013
Tolvaptan, a non-peptide V2-receptor antagonist, is a newly developed diuretic agent. Recently, we reported that tolvaptan has diuretic as well as anti-inflammatory and anti-fibrotic actions in chronic heart failure.
Takanori Yamazaki, Yasuhiro Nakamura, Masayuki Shiota, Mayuko Osada-Oka, Hiroyuki Fujiki, Akihisa Hanatani, Kenei Shimada, Katsuyuki Miura, Minoru Yoshiyama, Hiroshi Iwao, Yasukatsu Izumi   +10 more
doaj   +1 more source

Stereoselective Biotransformation: Transfer of Learning to Advance Drug Metabolism and Biocatalysis

Angewandte Chemie, Volume 138, Issue 25, 15 June 2026.
Understanding stereoselective biotransformations has implications for predicting drug disposition and response and may also inspire novel biocatalytic and biomimetic strategies to address challenges in metabolite and API synthesis. ABSTRACT Chirality is an important determinant of drug action, as enantiomers can exhibit markedly different ...
Grace A. Okunlola, Godwin A. Aleku
wiley   +2 more sources

Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan

Kidney Medicine, 2020
Rationale & Objective: Euvolemic hyponatremia often occurs due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin 2 receptor antagonists may be used to treat SIADH.
Ramy M. Hanna, Juan Carlos Velez, Anjay Rastogi, Minhtri K. Nguyen, Mohammad K. Kamgar, Kyaw Moe, Farid Arman, Huma Hasnain, Niloofar Nobakht, Umut Selamet, Ira Kurtz   +10 more
doaj   +1 more source

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients

Pharmacology Research & Perspectives, 2023
The optimal starting dose of tolvaptan to effectively improve fluid retention in patients with heart failure (HF) is unknown. This study explored the factors affecting the pharmacokinetics (PKs) and pharmacodynamics of tolvaptan in patients with ...
Takahiro Kato, Yoko Yasuda, Hitomi Okamoto, Yuji Saito, Yusuke Nakano, Katsuhiko Matsuura, Masafumi Oonishi, Tetsuya Amano   +7 more
doaj   +1 more source

Analysis of dose effect of tolvaptan on polycystic liver disease.

, 2022
To assess the dose effect of tolvaptan on the change in annual growth rate of total liver volume (TLV), the original tolvaptan group were stratified by daily dose of tolvaptan, less than 30mg, 60mg, 90mg, and mg. However, we could not find the any trends
Akinari Sekine (4357189), Eiko Hasegawa (848440), Naoki Sawa (848442), Hiroki Mizuno (560647), Tatsuya Suwabe (848436), Masayuki Yamanouchi (848441), Junichi Hoshino (848432), Daisuke Ikuma (12102061), Yoshifumi Ubara (848444)   +8 more
core   +1 more source

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort

Scientific Reports, 2023
Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not been systemically examined in a large cohort.
Luca Calvaruso, Kevin Yau, Pedram Akbari, Fatemah Nasri, Saima Khowaja, Bill Wang, Amirreza Haghighi, Korosh Khalili, York Pei   +8 more
doaj   +1 more source

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan

, 2020
Background and objectives: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity.
Bargagli, Matteo, Mariam Semmo, Fuster, Daniel G., Semmo, Mariam, Matteo Bargagli, Daniel G. Fuster, Anderegg, Manuel, Vogt, Bruno, Uyen Huynh-Do, Ferraro, Pietro Manuel, Huynh-Do, Uyen, Manuel Anderegg, Pietro Manuel Ferraro, Bruno Vogt, Dhayat, Nasser A., Nasser A. Dhayat   +15 more
core   +1 more source

Tolvaptan and urea in paediatric hyponatraemia [PDF]

, 2023
BACKGROUND: The syndrome of inappropriate antidiuretic hormone (SIADH) is usually treated with fluid restriction. This can be challenging in patients with obligate fluid intake for nutrition or medication. Pharmaceutical treatment with tolvaptan and urea
Amin, Rakesh, Alexandrou, Demitra, Gan, Hoong-Wei, Veligratli, Faidra, Bockenhauer, Detlef, Famuboni, Adeola, Lopez-Garcia, Camilo, Dattani, Mehul, Trompeter, Richard, Shah, Sarit   +9 more
core